Preparation for Beactica’s EIC Transition application
| Reference number | |
| Coordinator | Beactica Therapeutics AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | June 2025 - September 2025 |
| Status | Ongoing |
| Venture | Global cooperation 2025 |
| Call | Planning grant for international proposal 2025 |
Purpose and goal
The main goal of the project is to develop a strong application that will have a strong chance of obtaining a grant in the competitive EIC Transition programme.
Expected effects and result
Funding from EICT enables the completion of the preclinical block for the development of Beactica´s drug against glioblastoma, as well as the development of biomarkers to identify patients who can be helped by treatment with this drug.
Planned approach and implementation
The Proposal will be written in collaboration with an established project partner and a grant-writing consultancy firm.